Artificial Intelligence May Discover the Next Blockbuster Drug
AI is revolutionizing countless industries, but its biggest impact may be felt in medicine. Machine learning has proved capable of identifying signs of disease in medical images and records, and it may become invaluable for analyzing vast genomic data sets for clues as to the origins of different disorders. Benevolent AI, headquartered in London, is working to apply the latest AI techniques to the identification and development of novel drug compounds. The company’s CEO, Ken Mulvaney, met with MIT Technology Review’s senior editor for AI, Will Knight, to discuss AI’s relevance to drug discovery and medicine, and to talk about his company’s ambitious plans.
Geoffrey Hinton tells us why he’s now scared of the tech he helped build
“I have suddenly switched my views on whether these things are going to be more intelligent than us.”
ChatGPT is going to change education, not destroy it
The narrative around cheating students doesn’t tell the whole story. Meet the teachers who think generative AI could actually make learning better.
Meet the people who use Notion to plan their whole lives
The workplace tool’s appeal extends far beyond organizing work projects. Many users find it’s just as useful for managing their free time.
Learning to code isn’t enough
Historically, learn-to-code efforts have provided opportunities for the few, but new efforts are aiming to be inclusive.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.